Moolec Science SA Trading Halted Due to Volatility Trading Pause
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 30 2026
0mins
Should l Buy MLEC?
Moolec Science SA trading halted, volatility trading pause
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MLEC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MLEC
About MLEC
Moolec Science SA is a science based food ingredient company. The Company focuses on the production of animal proteins within plants by using molecular farming technology. It operates globally across the United States, Europe, and South America. The Company’s product portfolio and pipeline focus on improving the agronomic efficiency of widely used crops such as soy, pea, and safflower. Its product portfolio includes GLASO, PIGGY SOOY, VALORASOY, and MYCOFOOD. The Company’s GLASO product is a genetically engineered safflower variety designed to produce higher levels of gamma linolenic acid (GLA). Its PIGGY SOOY product is a bioengineered soybean that contains pig proteins used in creating meat like textures and food ingredients. The Company also has a growing international patent portfolio of approximately 25 patents, both granted and pending, for its technology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Rapt Therapeutics Acquired by GSK for $58 per Share, Valuing at $2.2 Billion
- Acquisition Deal: GSK has agreed to acquire Rapt Therapeutics for $58 per share, representing an estimated total equity value of $2.2 billion, which will significantly enhance GSK's market position in the biopharmaceutical sector.
- Stock Surge: Rapt Therapeutics' shares jumped 63.4% to $57.36 in pre-market trading, reflecting a positive market reaction to the acquisition, which may attract more investor interest in the company.
- Market Impact: This acquisition not only increases shareholder value for Rapt but may also prompt other biotech firms to consider similar strategic acquisitions to enhance their competitiveness and market share.
- Industry Outlook: With GSK's acquisition, Rapt's product development process is expected to accelerate, potentially leading to faster drug launches and further solidifying GSK's leadership position in the innovative pharmaceuticals market.
See More
PainReform Ltd. (PRFX) Announces Name Change, Shares Surge 27.4%
- Significant Stock Surge: PainReform Ltd. shares rose 27.4% to $1.02 in pre-market trading following the announcement of a name change and expansion into diversified healthcare and AI-driven energy platforms, indicating strong market confidence in its new strategy.
- Diversification Strategy: The name change reflects the company's strategic shift towards healthcare and energy sectors, aiming to attract more investors and enhance brand recognition, thereby strengthening its competitive position in the market.
- Market Movements: In pre-market trading, Acco Group Holdings saw a staggering 219.4% increase, highlighting strong investor interest in high-growth potential companies, which may influence perceptions of other related stocks.
- Industry Trends: As the integration of healthcare and energy sectors accelerates, PainReform's strategic adjustments align with industry developments and could provide the company with long-term growth opportunities.
See More
Gelteq Ltd Reports 22% Bioavailability Increase in Cannabinoid Oral Gel, Shares Surge 50.1%
- Bioavailability Improvement: Gelteq Ltd's oral gel delivery platform achieved over a 22% increase in bioavailability compared to an FDA-approved oil-based product in preclinical trials, indicating significant technological advantages that could enhance market acceptance and drive future sales growth.
- Stock Surge: Following this positive announcement, Gelteq's shares surged 50.1% in pre-market trading to $1.25, reflecting strong investor confidence in the new technology and its market potential.
- Enhanced Market Competitiveness: By improving product bioavailability, Gelteq not only meets the growing consumer demand but also positions itself more favorably in the competitive pharmaceutical market, potentially driving the company's long-term strategic development.
- Increased Investor Interest: With Gelteq's technological advancements and stock price increase, market attention on its future performance has significantly risen, likely attracting more investors and partners, thereby facilitating the company's capital operations and business expansion.
See More
Moolec Completes 15-for-1 Share Consolidation, Reducing Outstanding Shares to 726,118
- Share Consolidation Implementation: Moolec Science completed a 15-for-1 share consolidation on January 5, 2026, converting every 15 shares of $0.10 par value into 1 share of $1.50 par value, reducing outstanding shares from 10,891,761 to 726,118, aimed at enhancing per-share value and improving capital structure.
- Market Reaction Adjustment: The consolidation became effective on Nasdaq on January 5, 2026, with all shareholders' positions automatically adjusted, which is expected to boost investor confidence and potentially attract more institutional investors.
- Simplified Shareholder Actions: The consolidation process requires no action from shareholders, as positions held through brokers will be automatically adjusted, ensuring liquidity and convenience while enhancing corporate governance standards.
- Future Growth Potential: While the consolidation does not directly impact operations, Moolec's focus on molecular farming and precision fermentation positions the company to attract more investment in the future to support the development of sustainable protein solutions.
See More
Baidu Inc Proposes Spinoff of Kunlunxin H Shares, Stock Rises 12.3%
- Stock Surge: Baidu's announcement of a proposed spinoff of Kunlunxin (Beijing) Technology Co., Ltd. H shares for a separate listing on the Hong Kong Stock Exchange led to a 12.3% increase in its stock price to $146.69 in pre-market trading, indicating strong market enthusiasm for this strategic move.
- Spinoff Strategy: The spinoff aims to enhance Kunlunxin's independence and market valuation, which is expected to provide Baidu with more flexible capital operations and resource allocation, thereby strengthening its competitive position in the technology sector.
- Market Reaction: The spinoff news has sparked investor excitement, with the significant rise in Baidu's stock reflecting confidence in its future growth potential and likely attracting more institutional investors to its shares.
- Industry Impact: By pursuing this spinoff, Baidu can focus more on its core business while providing Kunlunxin with greater development space, which is anticipated to drive innovation and investment activity across the technology industry.
See More
Moolec Gets Nasdaq Determination Notification
Nasdaq Compliance Issue: Moolec Science SA received a notification from Nasdaq regarding non-compliance with Listing Rule 5250(c)(1) due to the delayed filing of its Annual Report on Form 20-F for the fiscal year ending June 30, 2025.
Business Combination Challenges: The delay in filing is attributed to complexities arising from a recent business combination, which involved intricate accounting processes, including reverse acquisition accounting and asset valuation.
Stay of Suspension Request: Moolec has requested a stay of suspension from the Nasdaq Hearings Panel, which has temporarily allowed the company's shares to continue trading under the symbol "MLEC" until a hearing on December 18, 2025.
Company Overview: Moolec Science focuses on innovative protein solutions through Molecular Farming and precision fermentation, holding a diverse pipeline and a strong intellectual property portfolio, with operations across the U.S., Europe, and South America.
See More
Rapt Therapeutics Acquired by GSK for $58 per Share, Valuing at $2.2 Billion
- Acquisition Deal: GSK has agreed to acquire Rapt Therapeutics for $58 per share, representing an estimated total equity value of $2.2 billion, which will significantly enhance GSK's market position in the biopharmaceutical sector.
- Stock Surge: Rapt Therapeutics' shares jumped 63.4% to $57.36 in pre-market trading, reflecting a positive market reaction to the acquisition, which may attract more investor interest in the company.
- Market Impact: This acquisition not only increases shareholder value for Rapt but may also prompt other biotech firms to consider similar strategic acquisitions to enhance their competitiveness and market share.
- Industry Outlook: With GSK's acquisition, Rapt's product development process is expected to accelerate, potentially leading to faster drug launches and further solidifying GSK's leadership position in the innovative pharmaceuticals market.
See More
PainReform Ltd. (PRFX) Announces Name Change, Shares Surge 27.4%
- Significant Stock Surge: PainReform Ltd. shares rose 27.4% to $1.02 in pre-market trading following the announcement of a name change and expansion into diversified healthcare and AI-driven energy platforms, indicating strong market confidence in its new strategy.
- Diversification Strategy: The name change reflects the company's strategic shift towards healthcare and energy sectors, aiming to attract more investors and enhance brand recognition, thereby strengthening its competitive position in the market.
- Market Movements: In pre-market trading, Acco Group Holdings saw a staggering 219.4% increase, highlighting strong investor interest in high-growth potential companies, which may influence perceptions of other related stocks.
- Industry Trends: As the integration of healthcare and energy sectors accelerates, PainReform's strategic adjustments align with industry developments and could provide the company with long-term growth opportunities.
See More
Gelteq Ltd Reports 22% Bioavailability Increase in Cannabinoid Oral Gel, Shares Surge 50.1%
- Bioavailability Improvement: Gelteq Ltd's oral gel delivery platform achieved over a 22% increase in bioavailability compared to an FDA-approved oil-based product in preclinical trials, indicating significant technological advantages that could enhance market acceptance and drive future sales growth.
- Stock Surge: Following this positive announcement, Gelteq's shares surged 50.1% in pre-market trading to $1.25, reflecting strong investor confidence in the new technology and its market potential.
- Enhanced Market Competitiveness: By improving product bioavailability, Gelteq not only meets the growing consumer demand but also positions itself more favorably in the competitive pharmaceutical market, potentially driving the company's long-term strategic development.
- Increased Investor Interest: With Gelteq's technological advancements and stock price increase, market attention on its future performance has significantly risen, likely attracting more investors and partners, thereby facilitating the company's capital operations and business expansion.
See More
Moolec Completes 15-for-1 Share Consolidation, Reducing Outstanding Shares to 726,118
- Share Consolidation Implementation: Moolec Science completed a 15-for-1 share consolidation on January 5, 2026, converting every 15 shares of $0.10 par value into 1 share of $1.50 par value, reducing outstanding shares from 10,891,761 to 726,118, aimed at enhancing per-share value and improving capital structure.
- Market Reaction Adjustment: The consolidation became effective on Nasdaq on January 5, 2026, with all shareholders' positions automatically adjusted, which is expected to boost investor confidence and potentially attract more institutional investors.
- Simplified Shareholder Actions: The consolidation process requires no action from shareholders, as positions held through brokers will be automatically adjusted, ensuring liquidity and convenience while enhancing corporate governance standards.
- Future Growth Potential: While the consolidation does not directly impact operations, Moolec's focus on molecular farming and precision fermentation positions the company to attract more investment in the future to support the development of sustainable protein solutions.
See More
Baidu Inc Proposes Spinoff of Kunlunxin H Shares, Stock Rises 12.3%
- Stock Surge: Baidu's announcement of a proposed spinoff of Kunlunxin (Beijing) Technology Co., Ltd. H shares for a separate listing on the Hong Kong Stock Exchange led to a 12.3% increase in its stock price to $146.69 in pre-market trading, indicating strong market enthusiasm for this strategic move.
- Spinoff Strategy: The spinoff aims to enhance Kunlunxin's independence and market valuation, which is expected to provide Baidu with more flexible capital operations and resource allocation, thereby strengthening its competitive position in the technology sector.
- Market Reaction: The spinoff news has sparked investor excitement, with the significant rise in Baidu's stock reflecting confidence in its future growth potential and likely attracting more institutional investors to its shares.
- Industry Impact: By pursuing this spinoff, Baidu can focus more on its core business while providing Kunlunxin with greater development space, which is anticipated to drive innovation and investment activity across the technology industry.
See More
Moolec Gets Nasdaq Determination Notification
Nasdaq Compliance Issue: Moolec Science SA received a notification from Nasdaq regarding non-compliance with Listing Rule 5250(c)(1) due to the delayed filing of its Annual Report on Form 20-F for the fiscal year ending June 30, 2025.
Business Combination Challenges: The delay in filing is attributed to complexities arising from a recent business combination, which involved intricate accounting processes, including reverse acquisition accounting and asset valuation.
Stay of Suspension Request: Moolec has requested a stay of suspension from the Nasdaq Hearings Panel, which has temporarily allowed the company's shares to continue trading under the symbol "MLEC" until a hearing on December 18, 2025.
Company Overview: Moolec Science focuses on innovative protein solutions through Molecular Farming and precision fermentation, holding a diverse pipeline and a strong intellectual property portfolio, with operations across the U.S., Europe, and South America.
See More
